BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors

BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors

Abstract The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of NK cell-based therapies, despite their proven safety and efficacy against cancer. Here, we describe the biological basis, detailed phenotype and function of long-lived anti-tumour human NK cells (...

Full description

Bibliographic Details
Main Authors: María-José Felgueres, Gloria Esteso, Álvaro F. García-Jiménez, Ana Dopazo, Nacho Aguiló, Carmen Mestre-Durán, Luis Martínez-Piñeiro, Antonio Pérez-Martínez, Hugh T. Reyburn, Mar Valés-Gómez
Format: Article
Language:English
Published: Nature Portfolio 2024-06-01
Series:Scientific Reports
Subjects:
Cancer immunology
Cell immunotherapy
NK cells
BCG
Cytokine activation
Online Access:https://doi.org/10.1038/s41598-024-62968-2

Internet

https://doi.org/10.1038/s41598-024-62968-2

Similar Items